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ABSTRACT: A convenient approach to [1,2,5]oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indoles and their heteroannulated analogues
bearing various aryl substituents in the backbone has been developed. This synthetic protocol is based on Pd-catalyzed Buchwald−
Hartwig and subsequent annulation by intramolecular oxidative cyclodehydrogenation. The photophysical properties for new
polycycles have been measured.
■ INTRODUCTION
Indolo[2,3-b]pyrazines are significant structural motifs pos-
sessing many important applications such as in medicinal
chemistry and material sciences (Figure 1). Namely, indolo-
[2,3-b]pyrazine derivatives display a wide range of promising
biological activities, such as antibacterial,1 anticancer,2 and
antiviral activities.3 Many indolopyrazine derivatives have also
been suggested as promising materials for organic electronics
such as organic light-emitting diodes,4 solar cells,5 and organic
transistor memory devices.6
There are five main routes for construction of the
indolopyrazine core that are described in the literature, and
they should be discussed to identify their weaknesses (Scheme
1). The most famous methods for the preparation of
indolopyrazine consist in the condensation of isatin with o-
phenylenediamine (route 1, Scheme 1)1,2c,6,7 or condensation
of in situ-generated 2,3-diaminoindole with α-dicarbonyl
compounds (route 2, Scheme 1).8 Generally, the main
limitations of these methods are obtaining regioisomeric
mixtures of indolopyrazines, when unsymmetrical o-phenyl-
enediamines or α-dicarbonyl compounds are used. Buchwald−
Hartwig amination followed by C−H activation from
secondary amines and 2,3-dibromoquinoxaline in one pot
(route 3, Scheme 1)9 and a two-step approach using Suzuki
cross-coupling and subsequent annulation by Pd-catalyzed
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Figure 1. Representative compound bearing the indolo[2,3-b]-
pyrazine core.
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twofold C−N coupling reactions with primary amines (route 4,
Scheme 1)10 afford indolo[2,3-b]pyrazines in high yield but
they similarly do not possess regioselectivity. Furthermore,
routes 3 and 4 have not corresponded the concept of the pot,
atom, and step economic (PASE)11 synthetic procedure
because it requires using 2,3-di(chloro)bromopyrazines that
is necessary for an additional introduction of halogens in the
pyrazine ring. Another regioselective method for the synthesis
of the indolopyrazines based on a sequential rhodium-
catalyzed formal [3+3] cycloaddition and aromatization
reaction of various diazoindolinimines with azirines.12 This
protocol requires a highly expensive and non-eco-friendly
rhodium catalyst and infrequent raw materials. All these
features eventually lead to the necessity of developing new
PASE processes to synthesize indolopyrazine and their
heteroanalogues that will be based on the metal-free oxidative
C−H bond functionalization (so-called SNH reaction).13
It should be mentioned that [1,2,5]oxadiazolo[3,4-b]-
pyrazine (so-called “ furazanopyrazine”) exhibits higher
electron-withdrawing character than similar nonannulated
pyrazine analogues and can be readily involved into the
metal-free oxidative C−H bond functionalization.14 Nowadays,
there is only one example of the synthesis of unsubstituted 5H-
[1,2,5]oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indole (I) and its
5-alkyl-substituted derivatives (II) as a new family of effective
inhibitors for the β-catenin/T-cell factor protein−protein
interaction (Scheme 2).15
By the foregoing, furazanopyrizine derivatives have been
selected as major precursors of novel aryl-substituted 5H-
[1,2,5]oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indoles.
■ RESULTS AND DISCUSSION
Synthesis. It has been found that the reaction of 5-(2-
bromophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine 1 with aniline
2a afforded 5-phenyl-5H-[1,2,5]oxadiazolo[3′,4′:5,6]pyrazino-
[2,3-b]indole 3a in good yield (Scheme 3). The conditions of
the domino reaction of 1 with aniline 2a were optimized
(Table 1). The ligand, palladium precursor, base, and solvent
were varied. The results showed that tricyclohexylphosphine
(PCy3) often gave better yields than other ligands. In fact, up
to 45% yield of 3a was achieved by employment of PCy3 as a
ligand in combination with Pd(OAc)2 as the Pd source (Table
1, entry 10).
With the optimized conditions in hand, we examined the
scope of the twofold C−N annulation reaction of 1 with
Scheme 1. Synthetic Routes to the Formation of the Indolo[2,3-b]pyrazine Scaffold
Scheme 2. Synthesis of 5H-[1,2,5]Oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indole (I) and its 5-Alkyl-Substituted Derivatives (II)
Scheme 3. Domino Synthesis of 5-Phenyl-5H-[1,2,5]oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indole 3a
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various anilines 2b−i and benzylamine 2j. The results showed
that the annulations gave the same yields for anilines bearing
both electron-withdrawing and -donating substituents. How-
ever, the domino reactions with sterically crowded ortho-2b,f
and meta-substituted 2c,g anilines have resulted in the
expected 5-aryl-5H-[1,2,5]oxadiazolo[3′,4′:5,6]pyrazino[2,3-
b]indole 3 in lower yields than with unsubstituted 2a and
para-substituted 2d,h anilines (Scheme 4). In contrast, the
reactions of 1 with alkylamines, using our optimized conditions
(Table 1, entry 10), resulted in the formation of side products
which were difficult to separate from the main product. The
appropriate result was only achieved for the synthesis of
product 3j derived from benzylamine in 59% yield. Structures
of 5H-[1,2,5]oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indoles were
verified by X-ray diffraction analysis performed for the single-
crystal sample of 5-(m-tolyl)-substituted derivative 3i (Figure
2), thus supporting the 1H and 13C NMR spectroscopic data.
A feasible reaction mechanism is depicted in Scheme 3. The
reaction between the 1 and aniline 2a proceeds through the
Buchwald−Hartwig amination, which gives intermediate A,
followed by an intramolecular nucleophilic attack at C(6)
position furazanopyrizine core B. The subsequent oxidation of
dihydropyrazine intermediate B by air oxygen leads to the
polycyclic system 3a.
To confirm this hypothesis, we carried out the reactions of
furazanopyrazine 1 with aniline 2a without using any palladium
catalyst only in the presence of various bases. It has been
shown that transition-metal-free oxidative dehydrogenation
cross-coupling reaction leads to 4a with the highest yield of
55% in the presence of sodium hydride as a base (Scheme 5).
Using these conditions allowed us to obtain a wide range of
corresponding SN
H products by the reaction of 1 with the same
series of amines. It is supposed that these reactions’ C−H
functionalization proceeds through nucleophilic substitution of
hydrogen according to the two-step “Addition−Oxidation”
mechanism.13
To increase the yields of polycyclic compounds 3, we have
carried out the annulation reaction of 4a in the earlier
developed best conditions of Buchwald−Hartwig amination
(Scheme 6). Unfortunately, despite yields of intramolecular
C−N coupling annulation being 72%, the two-step overall
yield of 3a from compound 1 to 3a achieved only to 40%.
The suggested approach to the construction of the
indolo[2,3-b]pyrazine core has also been applied successfully
for the synthesis of different indolopyrazines with annulated
benzene and/or thiophene rings (Scheme 7). In this regard, it
is noteworthy that the only reaction of 5-(3-bromothiophen-2-
yl)-[1,2,5]oxadiazolo[3,4-b]pyrazine 5a with aniline 2a yielded
Table 1. Optimization for the Synthesis of 3a
entry
Pd precursor
(equiv)
ligand
(20 mol %)
base
(2.5 equiv) solvent
yield
3a
(%)
1 Pd(PPh3)4
(5 mol %)
K3PO4 1,4-dioxane 0
2 Pd(PPh3)4
(10 mol %)
K3PO4 1,4-dioxane 9
3 Pd(PPh3)2Cl2
(10 mol %)
PPh3 K3PO4 1,4-dioxane 15
4 Pd2(dba)3
(10 mol %)
PCy3 K3PO4 1,4-dioxane 28
5 Pd(OAc)2
(10 mol %)
XantPhos K3PO4 1,4-dioxane 35
6 Pd(OAc)2
(10 mol %)
XPhos K3PO4 1,4-dioxane 33
7 Pd(OAc)2
(10 mol %)
PCy3 DABCO 1,4-dioxane 0
8 Pd(OAc)2
(10 mol %)
PCy3 K2CO3 1,4-dioxane 35
9 Pd(OAc)2
(10 mol %)
PCy3 K3PO4 1,4-dioxane 40
10 Pd(OAc)2
(10 mol %)
PCy3 K3PO4 toluene 45
Scheme 4. Synthesis and Structures of 5H-[1,2,5]Oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indole Derivatives 3a−j
Figure 2. ORTEP of 3i with thermal ellipsoids at the 50% probability
level.
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desired 8-phenyl-8H-[1,2,5]oxadiazolo[3,4-b]thieno-
[2′,3′:4,5]pyrrolo[2,3-e]pyrazine 7a and compound 6a as a
by-product. In other cases, the reactions of the bromine-
substituted derivatives 5b−d with aniline 2a led to the classic
Buchwald−Hartwig amination products 6b−d in 77−89%
yields. Notably, using PCy3 as a ligand for the palladium
Scheme 5. Synthesis and Structures of N-Aryl-6-(2-bromophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazin-5-amines 4a−i
Scheme 6. Synthesis of 5-Phenyl-5H-[1,2,5]oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indole 4a by Intramolecular Buchwald−
Hartwig Amination
Scheme 7. Synthesis of Heteroannulated Indolopyrazine Derivatives 7a−d
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catalyst in this case afforded products in yields only up to 40%,
while the replacement of it by Xantphos significantly increased
the yield of compounds 6b−d.
Further treatment of amination products 6b−d by acids,
followed by oxidation with air oxygen, also leads to similar
cyclization products 7b−d. Following the literature, trifluoro-
acetic acid16 was used for the cyclization of thiophenyl-
substituted quinoxaline 6b, while a mixture of hydrochloric
acid17 in ethanol led to the transformation of amino derivatives
6a,c into indolopyrazines 7c,b in high yields (Scheme 7).
■ CONCLUSIONS
In summary, we have described a convenient approach to
construct derivatives of a key heterocyclic system, namely,
[1,2,5]oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indoles, bearing
various substituents in the pyrrole fragment, based on domino
Pd-catalyzed Buchwald−Hartwig and subsequent annulation
by intramolecular oxidative cyclodehydrogenation reactions.
The two-step synthesis of other heteroannulated indolopyr-
azine analogues has been realized using this synthetic
approach. The further design and synthesis of different
indoloannulated derivatives using this reaction procedure, as
well as the elucidation of photophysical and electronic
properties of these polycyclic compounds, are currently in
progress.
■ EXPERIMENTAL SECTION
General Information. All reagents and solvents were
obtained from commercial sources and dried using standard
procedures before use. 1H and 13C NMR spectra were
obtained on Bruker DRX-400, AVANCE-500, and AVANCE-
600 spectrometers with TMS as internal standards. Elemental
analysis was carried out on a Eurovector EA 3000 automated
analyzer. Melting points were determined on Boetius
combined heating stages and were not corrected. All solvents
used were dried and distilled as per standard procedures. IR
spectra of samples (solid powders) were recorded on a
Spectrum One Fourier transform IR spectrometer (Perki-
nElmer) equipped with a diffuse reflectance attachment
(DRA). UV−vis spectra were recorded for ∼10−5 to 10−6 M
CH2Cl2 solutions with a Shimadzu UV-2401PC spectropho-
tometer. X-ray diffraction analysis was performed on an
automated X-ray diffractometer “Xcalibur E” based on the
standard procedure. The deposition number CCDC 1989238
for 3i contains the Supporting Information crystallographic
data for this paper. These data can be obtained free of charge
from the Cambridge Crystallographic Data Centre via www.
ccdc.cam.ac.uk/data_request/cif.
General Procedure for the Synthesis of 2-Bromo-
phenyl and 3-(Bromothiophen-2-yl)-Substituted 1,4-
Diazine Derivatives (1 and 5a−d). Selenium dioxide (1.1
g, 10 mmol) was dissolved in 1,4-dioxane/H2O 15:1 (16 mL)
and the mixture was heated at reflux for 5 min. 2′-
Bromoacetophenone [or 2-acetyl-3-bromothiophene] (10
mmol) was added and heating continued for next 12 h. The
reaction mixture was filtered and the filtrate was concentrated
under reduced pressure to give the corresponding aryl glyoxal
as light-yellow oil. The solution of 3,4-diaminofurazan [or 1,2-
phenylenediamine] (10 mmol) and crude aryl glyoxal in a
mixture of EtOH (5 mL) and CH3COOH (5 mL) was
refluxed for 1 h. After that, the mixture was cooled down, and
the precipitate was filtered off and washed with ethanol and
then air-dried.
5-(2-Bromophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine (1).
2′-Bromoacetophenone and 3,4-diaminofurazan were used
for the synthesis of product 1.
Yellow powder; yield 2.19 g (79%); mp 135 °C. 1H NMR
(500 MHz, DMSO-d6): δ 9.44 (s, 1H), 7.91 (dd, J = 8.0, 1.1
Hz, 1H), 7.79 (dd, J = 7.6, 1.7 Hz, 1H), 7.68 (td, J = 7.6, 1.1
Hz, 1H), 7.63−7.59 (m, 1H). 13C NMR (126 MHz, DMSO-
d6): δ 162.4, 157.1, 151.9, 151.1, 136.1, 133.4, 133.1, 132.4,
128.5, 121.0. Anal. Calcd for C10H5BrN4O (277.08): C, 43.35;
H, 1.87; N, 20.22. Found: C, 43.41; H, 1.84; N, 20.10.
5-(3-Bromothiophen-2-yl)-[1,2,5]oxadiazolo[3,4-b]-
pyrazine (5a). 2-Acetyl-3-bromothiophene and 3,4-diamino-
furazan were used for the synthesis of product 5a.
Pale yellow powder; yield 2.15 g (76%); mp 174−176 °C.
1H NMR (500 MHz, DMSO-d6): δ 9.79 (s, 1H), 8.19 (d, J =
5.3 Hz, 1H), 7.46 (d, J = 5.3 Hz, 1H). 13C NMR (126 MHz,
DMSO-d6): δ 154.5, 154.0, 151.9, 151.1, 135.3, 134.2, 134.1,
114.8. Anal. Calcd for C8H3BrN4OS (283.10): C, 33.94; H,
1.07; N, 19.79. Found: C, 33.92; H, 0.96; Br, 28.22; N, 19.69.
2-(3-Bromothiophen-2-yl)quinoxaline (5b). 2-Acetyl-3-
bromothiophene and 1,2-phenylenediamine were used for
the synthesis of product 5b.
Beige powder; yield 2.39 g (82%); mp 111−112 °C. 1H
NMR (500 MHz, DMSO-d6): δ 9.72 (s, 1H), 8.15−8.09 (m,
2H), 7.98 (d, J = 5.3 Hz, 1H), 7.93−7.88 (m, 2H), 7.36 (d, J =
5.3 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ 146.3, 142.7,
141.3, 140.7, 135.8, 132.8, 131.3, 131.1, 130.4, 128.9, 128.8,
109.8. Anal. Calcd for C12H7BrN2S (291.17): C, 49.50; H,
2.42; N, 9.62. Found: C, 49.54; H, 2.56; N, 9.38.
2-(2-Bromophenyl)pyrazine (5c). Commercially available
material 5c was used in our experiments.
2-(2-Bromophenyl)quinoxaline (5d). 2′-Bromoacetophe-
none and 1,2-phenylenediamine were used for the synthesis
of product 5b.
Pale yellow powder; yield 2.28 g (77%); mp 112−113 °C
(ref 18 116−118 °C). 1H NMR (400 MHz, CDCl3): δ 9.20 (s,
1H), 8.21 (td, J = 6.1, 3.2 Hz, 2H), 7.85 (dt, J = 6.4, 3.4 Hz,
2H), 7.76 (dd, J = 8.0, 1.2 Hz, 1H), 7.69 (dd, J = 7.7, 1.8 Hz,
1H), 7.52 (td, J = 7.5, 1.2 Hz, 1H), 7.39 (td, J = 7.7, 1.7 Hz,
1H). Anal. Calcd for C14H9BrN2 (285.14): C, 58.97; H, 3.18;
N, 9.82. Found: C, 58.88; H, 3.38; N, 9.69. Data similar to the
literature.18
General Procedure for the Synthesis of 5-Aryl-5H-
[1,2,5]oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indoles (3a−
j). A stirred mixture of 5-(2-bromophenyl)-[1,2,5]oxadiazolo-
[3,4-b]pyrazine (1) (135 mg, 0.5 mmol), corresponding
anilines (0.6 mmol), tricyclohexylphosphine (28 mg, 20 mol
%), Pd(OAc)2 (11 mg, 10 mol %), and K3PO4 (265 mg, 1.25
mmol) in degassed 1,4-dioxane (15 mL) was heated at reflux
under nitrogen for 15 h in a Schlenk tube. The reaction
mixture was cooled, filtered, acidified with concentrated
CH3COOH (1 mL), and dissolved with a mixture of EtOAc
and water 1:1 (50 mL), and the organic layer was separated.
The aqueous layer was extracted with EtOAc (2 × 25 mL).
The combined organic extracts were dried with MgSO4 and
the solvents were evaporated. The organic layer was separated,
dried over anhydrous Na2SO4, and concentrated. The crude
product was purified by column chromatography using hexane
and ethyl acetate as an eluent.
5-Phenyl-5H-[1,2,5]oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]-
indole (3a). Red powder; yield 65 mg (45%); mp 285−286
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°C. Rf 0.45 (CHCl3/hexane = 1:1, v/v).
1H NMR (400 MHz,
DMSO-d6): δ 8.41−8.38 (m, 1H), 7.83 (ddd, J = 8.4, 7.5, 1.3
Hz, 1H), 7.72−7.70 (m, 4H), 7.62 (ddt, J = 6.5, 4.9, 3.3 Hz,
1H), 7.50 (td, J = 7.6, 0.8 Hz, 1H), 7.32 (d, J = 8.2 Hz, 1H).
13C NMR (101 MHz, DMSO-d6): δ 153.2, 151.7, 151.5, 148.8,
135.8, 133.5, 130.0, 129.0, 127.1, 124.8, 123.6, 118.3, 111.4. IR
(DRA): 434, 446, 466, 496, 565, 592, 617, 627, 666, 691, 749,
775, 796, 807, 857, 880, 915, 946, 1008, 1019, 1030, 1057,
1081, 1110, 1168, 1180, 1128, 1259, 1307, 1330, 1379, 1445,
1486, 1502, 1551, 1586, 1598, 1621, 3079, 3099 cm−1. Anal.
Calcd for C16H9N5O (287.28): C, 66.89; H, 3.16; N, 24.38.
Found: C, 66.81; H, 3.18; N, 24.35.
5-(2-Methoxyphenyl)-5H-[1,2,5]oxadiazolo[3′,4′:5,6]-
pyrazino[2,3-b]indole (3b). Red powder; yield 22 mg (14%);
mp 248−250 °C. Rf 0.31 (CHCl3/hexane = 1:1, v/v). 1H
NMR (600 MHz, DMSO-d6): δ 8.38 (dd, J = 7.7, 1.2 Hz, 1H),
7.80 (ddd, J = 8.4, 7.4, 1.3 Hz, 1H), 7.67−7.63 (m, 1H), 7.61
(dd, J = 7.7, 1.7 Hz, 1H), 7.48 (td, J = 7.5, 0.9 Hz, 1H), 7.41
(dd, J = 8.5, 1.2 Hz, 1H), 7.25 (td, J = 7.6, 1.2 Hz, 1H), 7.05
(d, J = 8.1 Hz, 1H), 3.77 (s, 3H). 13C NMR (151 MHz,
DMSO-d6): δ 155.7, 153.3, 152.2, 152.1, 149.5, 136.4, 131.8,
130.2, 125.1, 123.9, 121.7, 118.5, 113.7, 112.5, 56.3. Anal.
Calcd for C17H11N5O2 (317.30): C, 64.35; H, 3.49; N, 22.07.
Found: C, 64.42; H, 3.45; N, 21.93.
5-(3-Methoxyphenyl)-5H-[1,2,5]oxadiazolo[3′,4′:5,6]-
pyrazino[2,3-b]indole (3c). Red powder; yield 76 mg (48%);
mp 258−260 °C. Rf 0.25 (CHCl3/hexane = 1:1, v/v). 1H
NMR (600 MHz, DMSO-d6): δ 8.42−8.37 (m, 1H), 7.83
(ddd, J = 8.4, 7.4, 1.3 Hz, 1H), 7.63 (t, J = 8.3 Hz, 1H), 7.50 (t,
J = 7.5 Hz, 1H), 7.36 (d, J = 8.2 Hz, 1H), 7.28 (dt, J = 3.6, 1.4
Hz, 2H), 7.21 (ddd, J = 8.4, 2.5, 1.0 Hz, 1H), 3.85 (s, 3H). 13C
NMR (151 MHz, DMSO-d6): δ 153.7, 152.2, 152.1, 152.0,
149.3, 136.4, 135.0, 131.3, 125.3, 124.1, 119.7, 118.8, 115.2,
113.4, 112.1, 56.0. Anal. Calcd for C17H11N5O2 (317.30): C,
64.35; H, 3.49; N, 22.07. Found: C, 64.30; H, 3.58; N, 22.09.
5-(4-Methoxyphenyl)-5H-[1,2,5]oxadiazolo[3′,4′:5,6]-
pyrazino[2,3-b]indole (3d). Orange powder; yield 95 mg
(60%); mp 271−273 °C. Rf 0.18 (CHCl3/hexane = 1:1, v/v).
1H NMR (500 MHz, DMSO-d6): δ 8.37 (ddd, J = 7.7, 1.3, 0.6
Hz, 1H), 7.81 (ddd, J = 8.5, 7.4, 1.3 Hz, 1H), 7.63−7.59 (m,
2H), 7.48 (td, J = 7.6, 0.8 Hz, 1H), 7.27−7.23 (m, 3H), 3.89
(s, 3H). 13C NMR (126 MHz, DMSO-d6): δ 159.4, 153.2,
151.7, 151.5, 149.2, 135.8, 128.6, 125.9, 124.7, 123.4, 118.2,
115.2, 111.4, 55.5. IR (DRA): 453, 464, 484, 529, 567, 592,
623, 635, 644, 694, 725, 755, 771, 788, 797, 804, 815, 835,
842, 852, 875, 911, 936, 953, 969, 987, 1007, 1015, 1028,
1058, 1111, 1155, 1180, 1232, 1263, 1304, 1326, 1384, 1445,
1465, 1488, 1518, 1552, 1595, 1610, 1619, 3009, 3062 cm−1.
Anal. Calcd for C17H11N5O2 (317.30): C, 64.35; H, 3.49; N,
22.07. Found: C, 64.51; H, 3.54; N, 22.26.
5-(3,4-Dimethoxyphenyl)-5H-[1,2,5]oxadiazolo[3′,4′:5,6]-
pyrazino[2,3-b]indole (3e). Red powder; yield 111 mg (64%);
mp 271−272 °C. Rf 0.28 (CHCl3/hexane = 1:1, v/v). 1H
NMR (500 MHz, DMSO-d6): δ 8.37 (dt, J = 7.7, 0.9 Hz, 1H),
7.81 (ddd, J = 8.4, 7.4, 1.3 Hz, 1H), 7.48 (td, J = 7.5, 0.8 Hz,
1H), 7.30 (d, J = 8.1 Hz, 1H), 7.26 (dd, J = 5.4, 3.2 Hz, 2H),
7.22 (dd, J = 8.5, 2.2 Hz, 1H), 3.89 (s, 3H), 3.78 (s, 3H). 13C
NMR (126 MHz, DMSO-d6): δ 153.2, 151.8, 151.5, 149.5,
149.4, 149.2, 135.8, 125.9, 124.6, 123.4, 119.8, 118.1, 112.3,
111.6, 110.9, 55.8. Anal. Calcd for C18H13N5O3 (347.33): C,
62.24; H, 3.77; N, 20.16. Found: C, 62.12; H, 3.61; N, 20.08.
5-(2-Nitrophenyl)-5H-[1,2,5]oxadiazolo[3′ ,4′ :5,6]-
pyrazino[2,3-b]indole (3f). Orange powder; yield 17 mg
(10%); mp 274−275 °C. Rf 0.45 (CHCl3/hexane = 1:1, v/v).
1H NMR (600 MHz, DMSO-d6): δ 8.51−8.36 (m, 2H), 8.12
(td, J = 7.7, 1.5 Hz, 1H), 7.98 (ddd, J = 8.3, 6.5, 1.6 Hz, 2H),
7.89−7.83 (m, 1H), 7.55 (t, J = 7.5 Hz, 1H), 7.29 (d, J = 8.2
Hz, 1H). 13C NMR (151 MHz, DMSO-d6): δ 153.1, 152.1,
151.9, 151.8, 148.8, 146.4, 136.7, 136.4, 132.0, 131.6, 127.0,
126.9, 125.5, 124.7, 118.8, 112.1. Anal. Calcd for C16H8N6O3
(332.27): C, 57.84; H, 2.43; N, 25.29. Found: C, 57.89; H,
2.34; N, 25.17.
5-(3-Nitrophenyl)-5H-[1,2,5]oxadiazolo[3′ ,4′ :5,6]-
pyrazino[2,3-b]indole (3g). Orange powder; yield 56 mg
(34%); mp 287−290 °C (decomp.). Rf 0.36 (CHCl3/hexane =
1:1, v/v). 1H NMR (600 MHz, DMSO-d6): δ 8.60 (t, J = 2.2
Hz, 1H), 8.48 (ddd, J = 8.3, 2.3, 1.0 Hz, 1H), 8.43 (dd, J = 7.7,
1.2 Hz, 1H), 8.23 (ddd, J = 7.9, 2.1, 1.0 Hz, 1H), 8.03 (t, J =
8.1 Hz, 1H), 7.86 (ddd, J = 8.5, 7.4, 1.3 Hz, 1H), 7.54 (td, J =
7.5, 0.8 Hz, 1H), 7.47 (d, J = 8.2 Hz, 1H). 13C NMR (151
MHz, DMSO-d6): δ 153.7, 152.2, 152.1, 152.0, 149.1, 148.7,
136.4, 135.0, 134.3, 132.1, 125.4, 124.5, 124.3, 122.9, 119.0,
112.0. Anal. Calcd for C16H8N6O3 (332.27): C, 57.84; H, 2.43;
N, 25.29. Found: C, 57.80; H, 2.25; N, 25.18.
5-(4-Nitrophenyl)-5H-[1,2,5]oxadiazolo[3′ ,4′ :5,6]-
pyrazino[2,3-b]indole (3h). Orange powder; yield 91 mg
(55%); mp 271−273 °C. Rf 0.35 (CHCl3/hexane = 1:1, v/v).
1H NMR (600 MHz, DMSO-d6): δ 8.60−8.56 (m, 2H), 8.44
(dd, J = 7.8, 1.2 Hz, 1H), 8.09−8.05 (m, 2H), 7.88 (ddd, J =
8.5, 7.4, 1.3 Hz, 1H), 7.57−7.52 (m, 2H). 13C NMR (151
MHz, DMSO-d6): δ 153.8, 152.2, 152.1, 152.0, 148.2, 147.2,
139.7, 136.4, 128.5, 125.8, 125.5, 124.7, 119.2, 112.2. IR
(DRA): 463, 477, 492, 529, 598, 623, 689, 709, 747, 770, 793,
804, 827, 853, 865, 885, 913, 944, 1012, 1025, 1044, 1061,
1109, 1159, 1174, 1228, 1296, 1324, 1353, 1377, 1421, 1446,
1464, 1487, 1504, 1524, 1552, 1590, 1614, 3077, 3118 cm−1.
Anal. Calcd for C16H8N6O3 (332.27): C, 57.84; H, 2.43; N,
25.29. Found: C, 57.54; H, 2.42; N, 25.15.
5-(m-Tolyl)-5H-[1,2,5]oxadiazolo[3′,4′:5,6]pyrazino[2,3-
b]indole (3i). Red powder; yield 93 mg (62%); mp 262−264
°C. Rf 0.47 (CHCl3/hexane = 1:1, v/v).
1H NMR (400 MHz,
DMSO-d6): δ 8.38 (d, J = 7.6 Hz, 1H), 7.87−7.77 (m, 1H),
7.60 (t, J = 7.7 Hz, 1H), 7.52−7.46 (m, 3H), 7.43 (d, J = 7.6
Hz, 1H), 7.31 (d, J = 8.2 Hz, 1H), 2.46 (s, 3H). 13C NMR
(101 MHz, DMSO-d6): δ 153.2, 151.7, 151.5, 148.8, 139.6,
135.8, 133.4, 129.8, 129.7, 127.4, 124.7, 124.2, 123.5, 118.3,
111.5, 20.9. Anal. Calcd for C17H11N5O (301.30): C, 67.77; H,
3.68; N, 23.24. Found: C, 67.88; H, 3.65; N, 23.41.
5-Benzyl-5H-[1,2,5]oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]-
indole (3j). Red powder; yield 89 mg (59%); mp 210−212 °C.
Rf 0.17 (CHCl3/hexane = 1:1, v/v).
1H NMR (600 MHz,
DMSO-d6): δ 8.35−8.30 (m, 1H), 7.81 (td, J = 7.8, 7.4, 1.3
Hz, 1H), 7.57 (d, J = 8.2 Hz, 1H), 7.50−7.44 (m, 2H), 7.42 (t,
J = 7.5 Hz, 1H), 7.34 (dd, J = 8.2, 6.6 Hz, 2H), 7.31−7.27 (m,
1H), 5.55 (s, 2H). 13C NMR (151 MHz, DMSO-d6): δ 153.6,
152.3, 152.3, 151.9, 148.5, 136.1, 136.0, 129.2, 128.2, 128.0,
125.2, 123.6, 118.8, 112.2, 44.9. Anal. Calcd for C17H11N5O
(301.30): C, 67.77; H, 3.68; N, 23.24. Found: C, 67.56; H,
3.81; N, 23.24.
General Procedure for the Synthesis of N-Aryl-6-(2-
bromophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazin-5-
amines (4a−i). A stirred mixture of 5-(2-bromophenyl)-
[1,2,5]oxadiazolo[3,4-b]pyrazine (1) (135 mg, 0.5 mmol),
corresponding anilines (0.6 mmol), and sodium hydride (24
mg, 1.0 mmol) in dry 1,4-dioxane (5 mL) was stirred at room
temperature for 48 h. The reaction mixture was acidified with
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concentrated CH3COOH (1 mL). The solvent was distilled off
in vacuo, and the crude product was purified by column
chromatography using hexane and ethyl acetate as an eluent.
6-(2-Bromophenyl)-N-phenyl-[1,2,5]oxadiazolo[3,4-b]-
pyrazin-5-amine (4a). Yellow powder; yield 65 mg (55%); mp
174−175 °C. Rf 0.26 (CHCl3/hexane = 1:1, v/v). 1H NMR
(600 MHz, DMSO-d6): δ 9.43 (s, 1H), 7.85 (dd, J = 8.1, 1.1
Hz, 1H), 7.76 (dd, J = 7.6, 1.7 Hz, 1H), 7.67 (td, J = 7.6, 1.2
Hz, 1H), 7.63−7.57 (m, 3H), 7.46−7.40 (m, 2H), 7.26 (tt, J =
7.3, 1.2 Hz, 1H). 13C NMR (151 MHz, DMSO-d6): δ 161.4,
152.4, 152.3, 150.2, 137.8, 133.5, 132.9, 132.0, 130.5, 129.0,
128.9, 127.6, 126.4, 124.8, 121.7. Anal. Calcd for
C16H10BrN5O (368.19): C, 52.19; H, 2.74; N, 19.02. Found:
C, 52.37; H, 2.63; N, 18.97.
6-(2-Bromophenyl)-N-(2-methoxyphenyl)-[1,2,5]-
oxadiazolo[3,4-b]pyrazin-5-amine (4b). Orange powder;
yield 108 mg (54%); mp 207−208 °C. Rf 0.42 (CHCl3/
hexane = 1:1, v/v). 1H NMR (600 MHz, DMSO-d6): δ 8.43 (s,
1H), 8.35−8.28 (m, 1H), 7.96 (d, J = 8.1 Hz, 1H), 7.82 (dd, J
= 7.5, 1.7 Hz, 1H), 7.75 (t, J = 7.5 Hz, 1H), 7.68 (td, J = 7.8,
1.7 Hz, 1H), 7.27−7.20 (m, 1H), 7.14−7.06 (m, 2H), 3.68 (s,
3H). 13C NMR (151 MHz, DMSO-d6): δ 161.2, 152.4, 151.2,
150.4, 150.1, 134.8, 133.7, 133.4, 131.6, 129.3, 126.8, 126.7,
122.0, 121.5, 121.3, 111.9, 56.7. Anal. Calcd for C17H12BrN5O2
(398.21): C, 51.27; H, 3.04; N, 17.59. Found: C, 51.50; H,
3.12; N, 17.81.
6-(2-Bromophenyl)-N-(3-methoxyphenyl)-[1,2,5]-
oxadiazolo[3,4-b]pyrazin-5-amine (4c). Yellow powder; yield
115 mg (58%); mp 171−172 °C. Rf 0.32 (CHCl3/hexane =
1:1, v/v). 1H NMR (600 MHz, DMSO-d6): δ 9.36 (s, 1H),
7.85 (dd, J = 8.1, 1.1 Hz, 1H), 7.75 (dd, J = 7.6, 1.7 Hz, 1H),
7.66 (td, J = 7.6, 1.2 Hz, 1H), 7.59 (ddd, J = 8.2, 7.4, 1.7 Hz,
1H), 7.34 (t, J = 8.1 Hz, 1H), 7.27−7.19 (m, 2H), 6.85 (ddd, J
= 8.3, 2.6, 1.0 Hz, 1H), 3.76 (s, 3H). 13C NMR (151 MHz,
DMSO-d6): δ 161.3, 159.7, 152.3, 152.2, 150.2, 139.0, 135.8,
133.5, 132.9, 132.1, 129.8, 128.9, 121.8, 117.0, 111.6, 110.6,
55.7. Anal. Calcd for C17H12BrN5O2 (398.21): C, 51.27; H,
3.04; N, 17.59. Found: C, 51.40; H, 2.97; N, 17.32.
6-(2-Bromophenyl)-N-(4-methoxyphenyl)-[1,2,5]-
oxadiazolo[3,4-b]pyrazin-5-amine (4d). Red powder; yield
125 mg (63%); mp 117−119 °C. Rf 0.35 (CHCl3/hexane =
1:1, v/v). 1H NMR (500 MHz, DMSO-d6): δ 9.34 (s, 1H),
7.84 (dd, J = 8.0, 1.1 Hz, 1H), 7.74 (dd, J = 7.6, 1.7 Hz, 1H),
7.65 (td, J = 7.5, 1.1 Hz, 1H), 7.58 (td, J = 7.8, 1.8 Hz, 1H),
7.53−7.45 (m, 2H), 7.02−6.97 (m, 2H), 3.77 (s, 3H). 13C
NMR (151 MHz, DMSO-d6): δ 161.5, 157.7, 152.5, 152.4,
150.2, 135.9, 133.5, 132.9, 131.9, 130.6, 128.9, 126.4, 121.7,
114.2, 55.8. Anal. Calcd for C17H12BrN5O2 (398.21): C, 51.27;
H, 3.04; N, 17.59. Found: C, 51.50; H, 3.21; N, 17.58.
6-(2-Bromophenyl)-N-(3,4-dimethoxyphenyl)-[1,2,5]-
oxadiazolo[3,4-b]pyrazin-5-amine (4e). Dark red powder;
yield 109 mg (51%); mp 166−167 °C. Rf 0.20 (CHCl3/hexane
= 1:1, v/v). 1H NMR (600 MHz, DMSO-d6): δ 9.29 (s, 1H),
7.97−7.84 (m, 1H), 7.75 (dd, J = 7.6, 1.8 Hz, 1H), 7.66 (td, J
= 7.6, 1.1 Hz, 1H), 7.59 (td, J = 7.8, 1.8 Hz, 1H), 7.29−7.22
(m, 1H), 7.15 (d, J = 2.4 Hz, 1H), 7.01 (d, J = 8.7 Hz, 1H),
3.78 (s, 3H), 3.73 (s, 3H). 13C NMR (151 MHz, DMSO-d6): δ
161.4, 152.5, 152.3, 150.2, 148.7, 147.4, 135.8, 133.5, 132.9,
131.9, 130.8, 128.9, 121.7, 117.2, 111.9, 109.3, 56.13, 56.11.
Anal. Calcd for C18H14BrN5O3 (428.24): C, 50.48; H, 3.30; N,
16.35. Found: C, 50.57; H, 3.28; N, 16.07.
6-(2-Bromophenyl)-N-(3-nitrophenyl)-[1,2,5]oxadiazolo-
[3,4-b]pyrazin-5-amine (4g). Dark orange powder; yield 52
mg (25%); mp 163−165 °C. Rf 0.15 (CHCl3/hexane = 1:1, v/
v). 1H NMR (600 MHz, DMSO-d6): δ 9.75 (s, 1H), 8.58 (t, J
= 2.2 Hz, 1H), 8.23 (ddd, J = 8.2, 2.1, 0.9 Hz, 1H), 8.10 (ddd,
J = 8.2, 2.3, 0.9 Hz, 1H), 7.88 (dd, J = 8.1, 1.1 Hz, 1H), 7.78
(dd, J = 7.6, 1.7 Hz, 1H), 7.74 (t, J = 8.2 Hz, 1H), 7.69 (td, J =
7.5, 1.1 Hz, 1H), 7.63 (td, J = 7.8, 1.8 Hz, 1H). 13C NMR (151
MHz, DMSO-d6): δ 161.0, 152.2, 151.9, 150.3, 148.2, 139.2,
135.6, 133.6, 133.1, 132.2, 130.4, 130.4, 128.9, 121.8, 120.6,
118.7. Anal. Calcd for C16H9BrN6O3 (413.19): C, 46.51; H,
2.20; N, 20.34. Found: C, 46.36; H, 2.19; N, 20.07.
6-(2-Bromophenyl)-N-(4-nitrophenyl)-[1,2,5]oxadiazolo-
[3,4-b]pyrazin-5-amine (4h). Orange powder; yield 79 mg
(38%); mp 200−202 °C. Rf 0.23 (CHCl3/hexane = 1:1, v/v).
1H NMR (600 MHz, DMSO-d6): δ 9.81 (s, 1H), 8.36−8.29
(m, 2H), 8.06−8.01 (m, 2H), 7.87 (dd, J = 8.1, 1.1 Hz, 1H),
7.78 (dd, J = 7.6, 1.7 Hz, 1H), 7.69 (td, J = 7.5, 1.1 Hz, 1H),
7.62 (td, J = 7.8, 1.8 Hz, 1H). 13C NMR (151 MHz, DMSO-
d6): δ 161.0, 151.9, 151.8, 150.3, 144.3, 144.2, 135.6, 133.6,
133.1, 132.4, 128.9, 124.8, 123.9, 121.8. Anal. Calcd for
C16H9BrN6O3 (413.19): C, 46.51; H, 2.20; N, 20.34. Found:
C, 46.71; H, 2.09; N, 20.36.
6-(2-Bromophenyl)-N-(m-tolyl)-[1,2,5]oxadiazolo[3,4-b]-
pyrazin-5-amine (4i). Yellow powder; yield 102 mg (51%);
mp 169−170 °C. Rf 0.50 (CHCl3/hexane = 1:1, v/v). 1H
NMR (500 MHz, DMSO-d6): δ 9.35 (s, 1H), 7.85 (dd, J = 8.1,
1.1 Hz, 1H), 7.75 (dd, J = 7.6, 1.8 Hz, 1H), 7.66 (td, J = 7.5,
1.1 Hz, 1H), 7.58 (td, J = 7.8, 1.8 Hz, 1H), 7.50−7.44 (m,
1H), 7.37 (d, J = 2.0 Hz, 1H), 7.31 (t, J = 7.8 Hz, 1H), 7.07
(ddt, J = 7.5, 1.8, 0.9 Hz, 1H), 2.32 (s, 3H). 13C NMR (126
MHz, DMSO-d6): δ 160.9, 151.9, 151.8, 149.7, 137.8, 137.2,
135.3, 133.0, 132.4, 131.5, 128.4, 128.3, 126.6, 124.7, 121.4,
121.2, 21.0. Anal. Calcd for C17H12BrN5O2 (398.21): C, 51.27;
H, 3.04; N, 17.59. Found: C, 51.37; H, 3.25; N, 17.54.
General Procedure for the Buchwald−Hartwig Cross-
Coupling Reaction for the Synthesis of Compounds 6a
and 7a. A stirred mixture of 5-(3-bromothiophen-2-yl)-
[1,2,5]oxadiazolo[3,4-b]pyrazine (5a) (142 mg, 0.5 mmol),
aniline (2a) (55 mg, 0.6 mmol), 4,5-bis(diphenylphosphino)-
9,9-dimethylxanthene (Xantphos) (58 mg, 20 mol %),
Pd(OAc)2 (11 mg, 10 mol %), and K3PO4 (265 mg, 1.25
mmol) in degassed 1,4-dioxane (15 mL) was heated at reflux
under nitrogen for 15 h in a Schlenk tube. The reaction
mixture was cooled, filtered, and dissolved with a mixture of
AcOEt and water 1:1 (50 mL), and the organic layer was
separated. The aqueous layer was extracted with AcOEt (2 ×
25 mL). The combined organic extracts were dried with
MgSO4 and the solvents were evaporated. The organic layer
was separated, dried over anhydrous Na2SO4, and concen-
trated. The crude products 6a and 7a were purified by column
chromatography using hexane and ethyl acetate as an eluent.
2-([1,2,5]Oxadiazolo[3,4-b]pyrazin-5-yl)-N-phenylthio-
phen-3-amine (6a). Violet powder; yield 15 mg (10%); mp
167−169 °C. Rf 0.12 (CHCl3/hexane = 1:1, v/v). 1H NMR
(500 MHz, DMSO-d6): δ 10.83 (s, 1H), 9.19 (s, 1H), 8.18 (d,
J = 5.5 Hz, 1H), 7.46−7.42 (m, 2H), 7.36−7.34 (m, 2H), 7.32
(d, J = 5.5 Hz, 1H), 7.18 (tt, J = 7.2, 1.2 Hz, 1H). 13C NMR
(126 MHz, DMSO-d6): δ 157.2, 154.2, 152.1, 151.3, 150.7,
140.1, 137.4, 129.7, 124.1, 120.7, 118.7, 111.7. Anal. Calcd for
C14H9N5OS (295.32): C, 56.94; H, 3.07; N, 23.71. Found: C,
56.72; H, 3.01; N, 23.48.
8-Phenyl-8H-[1,2,5]oxadiazolo[3,4-b]thieno[2′,3′:4,5]-
pyrrolo[2,3-e]pyrazine (7a). Orange powder; yield 109 mg
(74%); mp 274−275 °C. Rf 0.21 (CHCl3/hexane = 1:1, v/v).
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1H NMR (600 MHz, DMSO-d6): δ 8.54 (d, J = 5.1 Hz, 1H),
7.80−7.77 (m, 2H), 7.70−7.67 (m, 2H), 7.55 (td, J = 7.3, 1.2
Hz, 1H), 7.42 (d, J = 5.1 Hz, 1H). 13C NMR (151 MHz,
DMSO-d6): δ 159.4, 153.7, 151.6, 151.0, 148.0, 143.9, 135.1,
130.3, 128.7, 125.7, 114.6, 113.0. IR (DRA): 447, 485, 514,
556, 592, 606, 619, 649, 663, 675, 690, 704, 743, 759, 780,
793, 829, 859, 867, 882, 894, 915, 994, 1008, 1031, 1041,
1058, 1078, 1094, 1109, 1162, 1198, 1230, 1244, 1290, 1315,
1360, 1383, 1404, 1449, 1474, 1497, 1545, 1557, 1591, 3093,
3107 cm−1. Anal. Calcd for C14H7N5OS (293.30): C, 57.33; H,
2.41; N, 23.88. Found: C, 57.50; H, 2.47; N, 23.99.
General Procedure for the Buchwald−Hartwig Cross-
Coupling Reaction for the Synthesis of Compounds 6b,
6c, and 6d. A stirred mixture of N-phenyl-2-(quinoxalin-2-
yl)thiophen-3-amine (5b) [N-phenyl-2-(pyrazin-2-yl)aniline
(5c) or N-phenyl-2-(quinoxalin-2-yl)aniline (5d) (0.5
mmol), aniline (2a) (55 mg, 0.6 mmol), 4,5-bis(diphenyl-
phosphino)-9,9-dimethylxanthene (Xantphos) (58 mg, 20 mol
%), Pd(OAc)2 (11 mg, 10 mol %), and K3PO4 (265 mg, 1.25
mmol) in degassed 1,4-dioxane (15 mL) was heated at reflux
under nitrogen for 15 h in a Schlenk tube. The reaction
mixture was cooled, filtered, and dissolved with a mixture of
AcOEt and water 1:1 (50 mL), and the organic layer was
separated. The aqueous layer was extracted with AcOEt (2 ×
25 mL). The combined organic extracts were dried with
MgSO4 and the solvents were evaporated. The organic layer
was separated, dried over anhydrous Na2SO4, and concen-
trated. The crude products 6b−d were purified by column
chromatography using hexane and ethyl acetate as an eluent.
N-Phenyl-2-(quinoxalin-2-yl)thiophen-3-amine (6b). Or-
ange powder; yield 135 mg (89%); mp 148−150 °C. Rf 0.41
(CHCl3/hexane = 1:1, v/v).
1H NMR (500 MHz, DMSO-d6):
δ 10.38 (s, 1H), 9.11 (s, 1H), 8.10 (dd, J = 8.3, 1.3 Hz, 1H),
8.01 (dd, J = 8.2, 1.4 Hz, 1H), 7.85 (d, J = 5.4 Hz, 1H), 7.82
(ddd, J = 8.3, 6.9, 1.5 Hz, 1H), 7.72 (ddd, J = 8.3, 6.9, 1.4 Hz,
1H), 7.37−7.32 (m, 3H), 7.27−7.24 (m, 2H), 6.99 (tt, J = 7.3,
1.2 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ 148.8, 145.5,
143.9, 142.4, 140.2, 139.3, 130.7, 130.1, 129.5, 128.7, 128.4,
127.8, 121.4, 120.8, 117.9, 113.5. Anal. Calcd for C18H13N3S
(303.38): C, 71.26; H, 4.32; N, 13.85. Found: C, 71.07; H,
4.23; N, 13.84.
N-Phenyl-2-(pyrazin-2-yl)aniline (6c). Yellow powder; yield
98 mg (79%); mp 82−84 °C. Rf 0.37 (CHCl3/hexane = 1:1, v/
v). 1H NMR (500 MHz, DMSO-d6): δ 9.22 (s, 1H), 9.07 (d, J
= 1.5 Hz, 1H), 8.72 (t, J = 2.0 Hz, 1H), 8.57 (d, J = 2.6 Hz,
1H), 7.78 (d, J = 7.7 Hz, 1H), 7.38 (d, J = 4.0 Hz, 2H), 7.22 (t,
J = 7.8 Hz, 2H), 7.10−7.02 (m, 3H), 6.86 (t, J = 7.3 Hz, 1H).
13C NMR (126 MHz, DMSO-d6): δ 153.1, 144.4, 142.9, 142.8,
142.1, 142.0, 130.5, 130.5, 129.2, 124.3, 120.8, 120.6, 118.5,
117.9. Anal. Calcd for C16H13N3 (247.29): C, 77.71; H, 5.30;
N, 16.99. Found: C, 77.72; H, 5.29; N, 17.02.
N-Phenyl-2-(quinoxalin-2-yl)aniline (6d). Yellow powder;
yield 144 mg (77%); mp 122−123 °C. Rf 0.23 (CHCl3/hexane
= 1:1, v/v). 1H NMR (500 MHz, DMSO-d6): δ 9.93 (s, 1H),
9.38 (s, 1H), 8.22 (dd, J = 8.2, 1.5 Hz, 1H), 8.09 (dd, J = 8.2,
1.5 Hz, 1H), 8.03 (dd, J = 7.9, 1.5 Hz, 1H), 7.87 (dddd, J =
22.6, 8.4, 7.0, 1.5 Hz, 2H), 7.49−7.42 (m, 2H), 7.27 (dd, J =
8.5, 7.2 Hz, 2H), 7.20−7.15 (m, 2H), 7.10 (ddd, J = 8.1, 7.0,
1.4 Hz, 1H), 6.90 (tt, J = 7.2, 1.2 Hz, 1H). 13C NMR (126
MHz, DMSO-d6): δ 152.7, 145.8, 142.7, 142.5, 140.2, 139.9,
131.1, 130.9, 130.5, 129.7, 129.3, 128.7, 128.6, 123.6, 120.9,
120.5, 118.1, 117.9. Anal. Calcd for C20H15N3 (297.35): C,
80.78; H, 5.08; N, 14.13. Found: C, 80.70; H, 5.02; N, 14.20.
Synthesis of 4-Phenyl-4H-thieno[2′,3′:4,5]pyrrolo-
[2,3-b]quinoxaline (7b). The suspension of N-phenyl-2-
(quinoxalin-2-yl)thiophen-3-amine (6b) (152 mg, 0.5 mmol)
in trifluoroacetic acid (5 mL) was stirred at 50 °C for 24 h.
The solvent was removed under reduced pressure. The crude
product 7b was purified by column chromatography using
hexane and ethyl acetate as an eluent.
4-Phenyl-4H-thieno[2′,3′:4,5]pyrrolo[2,3-b]quinoxaline
(7b). Dark orange powder; yield 122 mg (81%); mp 200−201
°C. Rf 0.61 (CHCl3/hexane = 1:1, v/v).
1H NMR (500 MHz,
CDCl3): δ 8.03 (d, J = 8.0 Hz, 1H), 7.85 (dd, J = 40.7, 8.1 Hz,
2H), 7.52 (dt, J = 21.7, 7.3 Hz, 2H), 7.31−7.21 (m, 2H), 7.07
(t, J = 7.5 Hz, 1H), 6.55 (dd, J = 62.2, 6.7 Hz, 2H), 5.96 (s,
1H). 13C NMR (126 MHz, CDCl3): δ 150.1, 147.6, 147.2,
141.6, 141.4, 133.5, 131.2, 130.4, 129.7, 129.0, 128.4, 127.9,
126.7, 123.9, 121.7, 119.1. IR (DRA): 511, 538, 572, 607, 647,
698, 718, 737, 753, 789, 804, 841, 866, 894, 944, 974, 1017,
1048, 1062, 1100, 1128, 1139, 1164, 1190, 1209, 1234, 1272,
1313, 1348, 1380, 1402, 1430, 1446, 1482, 1516, 1529, 1577,
1596, 1618, 3057, 3099, 3181, 3279 cm−1. Anal. Calcd for
C18H11N3S (301.37): C, 71.74; H, 3.68; N, 13.94. Found: C,
71.86; H, 3.35; N, 14.07.
General Procedure for the Synthesis of 5-Phenyl-5H-
pyrazino[2,3-b]indole (7c) and 6-Phenyl-6H-indolo[2,3-
b]quinoxaline (7d). The suspension of N-phenyl-2-(pyrazin-
2-yl)aniline (6c) [or N-phenyl-2-(quinoxalin-2-yl)aniline
(6d)] (0.5 mmol) in EtOH/conc. HCl (10 mL, v/v 99:1)
was refluxed for 1 h. The solvent was removed under reduced
pressure. The crude products 7c and 7d were purified by
column chromatography using hexane and ethyl acetate as an
eluent.
5-Phenyl-5H-pyrazino[2,3-b]indole (7c). Beige powder;
yield 98 mg (80%); mp 158−160 °C. Rf 0.52 (EtOAc/hexane
= 1:2, v/v). 1H NMR (500 MHz, CDCl3): δ 8.56 (d, J = 2.7
Hz, 1H), 8.43 (dt, J = 7.8, 1.0 Hz, 1H), 8.40 (d, J = 2.7 Hz,
1H), 7.65−7.60 (m, 4H), 7.59 (dd, J = 7.0, 1.3 Hz, 1H), 7.55
(d, J = 8.1 Hz, 1H), 7.50 (tt, J = 5.8, 2.6 Hz, 1H), 7.44 (ddd, J
= 8.0, 7.0, 1.2 Hz, 1H). 13C NMR (126 MHz, CDCl3): δ
145.8, 141.4, 139.8, 137.6, 136.6, 135.3, 129.8, 129.3, 128.1,
127.1, 121.8, 121.7, 119.9, 110.7. IR (DRA): 449, 492, 533,
569, 594, 619, 638, 655, 695, 715, 740, 748, 762, 794, 804,
845, 866, 906, 936, 951, 973, 1012, 1024, 1077, 1104, 1149,
1157, 1171, 1211, 1230, 1270, 1281, 1304, 1327, 1344, 1407,
1456, 1477, 1503, 1545, 1579, 1596, 1621, 3055, 3072 cm−1.
Anal. Calcd for C16H11N3 (245.28): C, 78.35; H, 4.52; N,
17.13. Found: C, 78.34; H, 4.76; N, 17.16.
6-Phenyl-6H-indolo[2,3-b]quinoxaline (7d). Pale yellow
powder; yield 109 mg (74%); mp 237−238 °C. Rf 0.32
(CHCl3/hexane = 1:1, v/v).
1H NMR (500 MHz, CDCl3): δ
8.57−8.51 (m, 1H), 8.32 (dd, J = 7.9, 1.9 Hz, 1H), 8.09 (dd, J
= 7.9, 1.9 Hz, 1H), 7.77−7.62 (m, 7H), 7.54−7.49 (m, 2H),
7.44 (t, J = 7.5 Hz, 1H). 13C NMR (126 MHz, CDCl3): δ
145.8, 144.7, 140.5, 140.1, 139.8, 135.4, 131.0, 129.8, 129.2,
128.8, 128.2, 127.9, 127.1, 126.5, 122.6, 121.8, 119.8, 110.6. IR
(DRA): 591, 619, 650, 695, 720, 749, 767, 781, 802, 830, 859,
909, 924, 955, 1007, 1016, 1027, 1043, 1074, 1101, 1134,
1148, 1175, 1207, 1228, 1254, 1305, 1320, 1337, 1355, 1392,
1405, 1460, 1471, 1484, 1504, 1583, 1598, 1609, 1629, 3057
cm−1. Anal. Calcd for C20H13N3 (295.34): C, 81.34; H, 4.44;
N, 14.23. Found: C, 81.30; H, 4.51; N, 14.21.
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c01945
ACS Omega 2020, 5, 15681−15690
15688
■ ASSOCIATED CONTENT
*sı Supporting Information
The Supporting Information is available free of charge at
https://pubs.acs.org/doi/10.1021/acsomega.0c01945.
Crystallographic data for 3i (CIF)
Experimental procedures, UV−vis absorption spectra of
compounds 3a, 3d, 3h, and 7a−d, characterization data
for all new compounds, and 1H and 13C NMR spectra
(PDF)
■ AUTHOR INFORMATION
Corresponding Author
Egor V. Verbitskiy − I. Postovsky Institute of Organic Synthesis,
Ural Branch of the Russian Academy of Sciences, Ekaterinburg
620108, Russia; Ural Federal University, Ekaterinburg 620002,
Russia; orcid.org/0000-0002-9613-8738;
Email: verbitsky@ios.uran.ru
Authors
Yuriy A. Kvashnin − I. Postovsky Institute of Organic Synthesis,
Ural Branch of the Russian Academy of Sciences, Ekaterinburg
620108, Russia
Ekaterina F. Zhilina − I. Postovsky Institute of Organic
Synthesis, Ural Branch of the Russian Academy of Sciences,
Ekaterinburg 620108, Russia
Gennady L. Rusinov − I. Postovsky Institute of Organic
Synthesis, Ural Branch of the Russian Academy of Sciences,
Ekaterinburg 620108, Russia; Ural Federal University,
Ekaterinburg 620002, Russia
Oleg N. Chupakhin − I. Postovsky Institute of Organic
Synthesis, Ural Branch of the Russian Academy of Sciences,
Ekaterinburg 620108, Russia; Ural Federal University,
Ekaterinburg 620002, Russia; orcid.org/0000-0002-1672-
2476
Valery N. Charushin − I. Postovsky Institute of Organic
Synthesis, Ural Branch of the Russian Academy of Sciences,
Ekaterinburg 620108, Russia; Ural Federal University,
Ekaterinburg 620002, Russia
Complete contact information is available at:
https://pubs.acs.org/10.1021/acsomega.0c01945
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
This work was supported by the Russian Foundation for Basic
Research (research project no. 18-29-23045 mk). Y.A.K. would
like to acknowledge the financial support for the part of the
synthetic section from the Russian Foundation for Basic
Research (research project no. 18-33-00103-mol_a).
■ REFERENCES
(1) (a) Pai, N. R.; Pusalkar, D. A. Pharmacological screening of
novel indolo[2,3-b]quinoxaline derivatives. J. Chem. Pharm. Res. 2010,
2, 485−493. (b) Manna, K.; Agrawal, Y. K. Microwave assisted
synthesis of new indophenazine 1,3,5-trisubstruted pyrazoline
derivatives of benzofuran and their antimicrobial activity. Bioorg.
Med. Chem. Lett. 2009, 19, 2688−2692.
(2) (a) Hirata, K.; Araya, J.; Nakaike, S.; Kitamura, K.; Ishida, T.
Side Chain-Dependent Binding of Antitumor Indoloquinoxaline
Derivatives to DNA: Comparative Spectroscopic and Viscometric
Measurements. Chem. Pharm. Bull. 2001, 49, 44−48. (b) Deady, L.
W.; Kaye, A. J.; Finlay, G. J.; Baguley, B. C.; Denny, W. A. Synthesis
and Antitumor Properties of N-[2-(Dimethylamino)ethyl]-
carboxamide Derivatives of Fused Tetracyclic Quinolines and
Quinoxalines: A New Class of Putative Topoisomerase Inhibitors. J.
Med. Chem. 1997, 40, 2040−2046. (c) Avula, S.; Komsani, J. R.;
Koppireddi, S.; Yadla, R.; Kanugula, A. K.; Kotamraju, S. Synthesis
and cytotoxicity of novel 6H-indolo[2,3-b]quinoxaline derivatives.
Med. Chem. Res. 2013, 22, 3712−3718.
(3) (a) Harmenberg, J.; Wahren, B.; Bergman, J.; Akerfeldt, S.;
Lundblad, L. Antiherpesvirus activity and mechanism of action of
indolo-(2,3-b)quinoxaline and analogs. Antimicrob. Agents Chemother.
1988, 32, 1720−1724. (b) Harmenberg, J.; Åkesson-Johansson, A.;
Gras̈lund, A.; Malmfors, T.; Bergman, J.; Wahren, B.; Åkerfeldt, S.;
Lundblad, L.; Cox, S. The mechanism of action of the anti-herpes
virus compound 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-
(2,3-b)quinoxaline. Antiviral Res. 1991, 15, 193−204.
(4) (a) Su, T.-H.; Fan, C.-H.; Ou-Yang, Y.-H.; Hsu, L.-C.; Cheng,
C.-H. Highly efficient deep-red organic electrophosphorescent devices
with excellent operational stability using bis(indoloquinoxalinyl)
derivatives as the host materials. J. Mater. Chem. C 2013, 1, 5084−
5092. (b) Tyagi, P.; Venkateswararao, A.; Thomas, K. R. J. Solution
Processable Indoloquinoxaline Derivatives Containing Bulky Poly-
aromatic Hydrocarbons: Synthesis, Optical Spectra, and Electro-
luminescence. J. Org. Chem. 2011, 76, 4571−4581. (c) Fan, C.-H.;
Sun, P.; Su, T.-H.; Cheng, C.-H. Host and Dopant Materials for
Idealized Deep-Red Organic Electrophosphorescence Devices. Adv.
Mater. 2011, 23, 2981−2985.
(5) Thomas, K. R. J.; Tyagi, P. Synthesis, Spectra, and Theoretical
Investigations of the Triarylamines Based on 6H-Indolo[2,3-b]-
quinoxaline. J. Org. Chem. 2010, 75, 8100−8111.
(6) Zhao, J.; Li, H.; Li, H.; Zhao, Q.; Ling, H.; Li, J.; Lin, J.; Xie, L.;
Lin, Z.; Yi, M.; Huang, W. Synthesis, characterization and charge
storage properties of π-biindolo[2,3-b]quinoxaline for solution-
processing organic transistor memory. Dyes Pigm. 2019, 167, 255−
261.
(7) (a) Dandia, A.; Parewa, V.; Maheshwari, S.; Rathore, K. S. Cu
doped CdS nanoparticles: A versatile and recoverable catalyst for
chemoselective synthesis of indolo[2,3-b]quinoxaline derivatives
under microwave irradiation. J. Mol. Catal. A: Chem. 2014, 394,
244−252. (b) Edayadulla, N.; Lee, Y. R. Cerium oxide nanoparticle-
catalyzed three-component protocol for the synthesis of highly
substituted novel quinoxalin-2-amine derivatives and 3,4-dihydroqui-
noxalin-2-amines in water. RSC Adv. 2014, 4, 11459−11468.
(8) Mannes, P. Z.; Onyango, E. O.; Gribble, G. W. Synthesis of a
Masked 2,3-Diaminoindole. J. Org. Chem. 2016, 81, 12478−12481.
(9) (a) Ackermann, L.; Althammer, A.; Mayer, P. Palladium-
Catalyzed Direct Arylation-Based Domino Synthesis of Annulated N-
Heterocycles Using Alkenyl or (Hetero)Aryl 1,2-Dihalides. Synthesis
2009, 2009, 3493−3503. (b) Ackermann, L.; Althammer, A. Domino
N-H/C-H bond activation: palladium-catalyzed synthesis of annu-
lated heterocycles using dichloro(hetero)arenes. Angew. Chem., Int.
Ed. 2007, 46, 1627−1629. (c) Hung, T. Q.; Hoang, D. H.; Thang, N.
N.; Dang, T. T.; Ayub, K.; Villinger, A.; Friedrich, A.; Lochbrunner,
S.; Flechsig, G.-U.; Langer, P. Palladium catalyzed synthesis and
physical properties of indolo[2,3-b]quinoxalines. Org. Biomol. Chem.
2014, 12, 6151−6166.
(10) Hung, T. Q.; Dang, T. T.; Villinger, A.; Sung, T. V.; Langer, P.
Efficient synthesis of thieno[3,2-b:4,5-b′]diindoles and benzothieno-
[3,2-b]indoles by Pd-catalyzed site-selective C−C and C−N coupling
reactions. Org. Biomol. Chem. 2012, 10, 9041−9044.
(11) (a) Trost, B. The atom economy–a search for synthetic
efficiency. Science 1991, 254, 1471−1477. (b) Trost, B. M. Atom
EconomyA Challenge for Organic Synthesis: Homogeneous
Catalysis Leads the Way. Angew. Chem., Int. Ed. Engl. 1995, 34,
259−281.
(12) Baek, Y.; Maeng, C.; Kim, H.; Lee, P. H. Regioselective
Synthesis of Indolopyrazines through a Sequential Rhodium-
Catalyzed Formal [3+3] Cycloaddition and Aromatization Reaction
of Diazoindolinimines with Azirines. J. Org. Chem. 2018, 83, 2349−
2360.
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c01945
ACS Omega 2020, 5, 15681−15690
15689
(13) For selected reviews on the metal-free oxidative C−H bond
functionalization, see: (a) Chupakhin, O. N.; Charushin, V. N.; Van
der Plas, H. C. Nucleophilic Aromatic Substitution of Hydrogen;
Academic Press: New York, San Diego, 1994. (b) Charushin, V. N.;
Chupakhin, O. N. SN
H methodology and new approaches to
condensed heterocyclic systems. Pure Appl. Chem. 2004, 76, 1621−
1631. (c) Charushin, V. N.; Chupakhin, O. N. Nucleophilic aromatic
substitution of hydrogen and related reactions. Mendeleev Commun.
2007, 17, 249−254. (d) Ma ̧kosza, M.; Wojciechowski, K.
Nucleophilic Substitution of Hydrogen in Heterocyclic Chemistry.
Chem. Rev. 2004, 104, 2631−2666. (e) Mąkosza, M. Nucleophilic
substitution of hydrogen in electron-deficient arenes, a general
process of great practical value. Chem. Soc. Rev. 2010, 39, 2855−2868.
(f) Topics in Heterocyclic Chemistry; Charushin, V. N., Chupakhin, O.
N., Eds.; Springer International Publishing: Switzerland, 2013; pp 1−
50. (g) Makosza, M.; Wojciechowski, K. In Topics in Heterocyclic
Chemistry; Charushin, V. N., Chupakhin, O. N., Eds.; Springer
International Publishing: Switzerland, 2013; pp 51−105. (h) Verbit-
skiy, E.; Rusinov, G.; Chupakhin, O.; Charushin, V. Recent Advances
in Direct C−H Functionalization of Pyrimidines. Synthesis 2018, 50,
193−210.
(14) (a) Sheremetev, A. B.; Yudin, I. L. Advances in the chemistry of
furazano[3,4-b]pyrazines and their analogues. Russ. Chem. Rev. 2003,
72, 87−100. (b) Kvashnin, Y. A.; Kazin, N. A.; Verbitskiy, E. V.;
Svalova, T. S.; Ivanova, A. V.; Kozitsina, A. N.; Slepukhin, P. A.;
Rusinov, G. L.; Chupakhin, O. N.; Charushin, V. N. A facile, metal-
free, oxidative coupling of new 6-(hetero)aryl-[1,2,5]oxadiazolo[3,4-
b]pyrazines with pyrroles, indoles and carbazoles. ARKIVOC 2016,
2016, 279−300. (c) Verbitskiy, E. V.; Kvashnin, Y. A.; Slepukhin, P.
A.; Kuchin, A. V.; Rusinov, G. L.; Chupakhin, O. N.; Charushina, V.
N. Reactions of pyrazinium salts with phenols:from σH-adducts to SN
H
products and transformations into benzo[b]furans. Russ. Chem. Bull.
2011, 60, 919−928. (d) Verbitskiy, E. V.; Kvashnin, Y. A.; Baranova,
A. A.; Yakovleva, Y. A.; Khokhlov, K. O.; Rusinov, G. L.; Charushin,
V. N. 9-Ethyl-3-{6-(het)aryl-[1,2,5]oxadiazolo[3,4-b]pyrazin-5-yl}-
9H-carbazoles: synthesis and study of sensitivity to nitroaromatic
compounds. Russ. Chem. Bull. 2018, 67, 1078−1082. (e) Utepova, I.
A.; Musikhina, A. A.; Kvashnin, Y. A.; Shcherbakova, M. A.;
Serebrennikova, P. O.; Rusinov, G. L.; Chupakhin, O. N. Direct C-
C-coupling of ferrocenyl- and cymantrenyllithium with 5-(het)aryl-
1,2,5-oxadiazolo[3,4-b]pyrazines. Russ. Chem. Bull. 2011, 60, 2531−
2535. (f) Kazin, N. A.; Kvashnin, Y. A.; Irgashev, R. A.; Dehaen, W.;
Rusinov, G. L.; Charushin, V. N. Direct arylalkenylation of
furazano[3,4-b]pyrazines via a new C−H functionalization protocol.
Tetrahedron Lett. 2015, 56, 1865−1869. (g) Tsyganov, D. V.; Samet,
A. V.; Dorovatovskii, P. V.; Khrustalev, V. N.; Semenov, V. V.
Arylglyoxal oximes as putative C-nucleophiles in eliminative
nucleophilic substitution process. Mendeleev Commun. 2019, 29,
296−298.
(15) Catrow, J. L.; Zhang, Y.; Zhang, M.; Ji, H. Discovery of
Selective Small-Molecule Inhibitors for the β-Catenin/T-Cell Factor
Protein−Protein Interaction through the Optimization of the Acyl
Hydrazone Moiety. J. Med. Chem. 2015, 58, 4678−4692.
(16) Verbitskiy, E. V.; Cheprakova, E. M.; Slepukhin, P. A.; Kodess,
M. I.; Ezhikova, M. A.; Pervova, M. G.; Rusinov, G. L.; Chupakhin, O.
N.; Charushin, V. N. Combination of the Suzuki−Miyaura cross-
coupling and nucleophilic aromatic substitution of hydrogen (SN
H)
reactions as a versatile route to pyrimidines bearing thiophene
fragments. Tetrahedron 2012, 68, 5445−5452.
(17) Ponizovsky, M. G.; Boguslavsky, A. M.; Kodess, M. I.;
Charushin, V. N.; Chupakhin, O. N. Synthesis of fused quinoxalines.
Mendeleev Commun. 2002, 12, 68−70.
(18) Loukrakpam, D. C.; Phukan, P. TsNBr2 Mediated Synthesis of
2-Acylbenzothiazoles and Quinoxalines from Aryl Methyl Ketones
under Metal Free Condition. ChemistrySelect 2019, 4, 3180−3184.
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c01945
ACS Omega 2020, 5, 15681−15690
15690
